Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,008 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG; ReSTORE trial investigators. Thompson GR 3rd, et al. Among authors: bassetti m. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. Lancet. 2023. PMID: 36442484 Free article. Clinical Trial.
European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study.
Arendrup MC, Arikan-Akdagli S, Jørgensen KM, Barac A, Steinmann J, Toscano C, Arsenijevic VA, Sartor A, Lass-Flörl C, Hamprecht A, Matos T, Rogers BRS, Quiles I, Buil J, Özenci V, Krause R, Bassetti M, Loughlin L, Denis B, Grancini A, White PL, Lagrou K, Willinger B, Rautemaa-Richardson R, Hamal P, Ener B, Unalan-Altintop T, Evren E, Hilmioglu-Polat S, Oz Y, Ozyurt OK, Aydin F, Růžička F, Meijer EFJ, Gangneux JP, Lockhart DEA, Khanna N, Logan C, Scharmann U, Desoubeaux G, Roilides E, Talento AF, van Dijk K, Koehler P, Salmanton-García J, Cornely OA, Hoenigl M. Arendrup MC, et al. Among authors: bassetti m. J Infect. 2023 Nov;87(5):428-437. doi: 10.1016/j.jinf.2023.08.001. Epub 2023 Aug 6. J Infect. 2023. PMID: 37549695 Free article.
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR 3rd, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, Kullberg BJ, Pullman J, Hites M, Fortún J, Horcajada JP, Kotanidou A, Das AF, Sandison T, Aram JA, Vazquez JA, Pappas PG. Thompson GR 3rd, et al. Among authors: bassetti m. Lancet Infect Dis. 2024 Mar;24(3):319-328. doi: 10.1016/S1473-3099(23)00551-0. Epub 2023 Nov 23. Lancet Infect Dis. 2024. PMID: 38008099 Free article. Clinical Trial.
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study.
Soriano A, Honore PM, Cornely OA, Chayakulkeeree M, Bassetti M, Haihui H, Dupont H, Kim YK, Kollef M, Kullberg BJ, Manamley N, Pappas P, Pullman J, Sandison T, Dignani C, Vazquez JA, Thompson GR 3rd. Soriano A, et al. Among authors: bassetti m. Clin Infect Dis. 2024 Sep 26;79(3):672-681. doi: 10.1093/cid/ciae363. Clin Infect Dis. 2024. PMID: 38985561 Free PMC article. Clinical Trial.
Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin.
Soriano A, Locke JB, Cornely OA, Roilides E, Ramos-Martinez A, Honoré PM, Castanheira M, Carvalhaes CG, Nseir S, Bassetti M, Manamley N, Sandison T, Arendrup MC. Soriano A, et al. Among authors: bassetti m. Clin Microbiol Infect. 2024 Nov 22:S1198-743X(24)00560-3. doi: 10.1016/j.cmi.2024.11.029. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 39581541 Free article.
Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031).
Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, Marchetti O, de Burghgraeve P, Ramadan S, Pylkkanen L, Ameye L, Paesmans M, Donnelly JP; EORTC Infectious Diseases Group. Cornely OA, et al. Among authors: bassetti m. Clin Infect Dis. 2015 Aug 1;61(3):324-31. doi: 10.1093/cid/civ293. Epub 2015 Apr 13. Clin Infect Dis. 2015. PMID: 25870323
REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T, Gentile I, Cattelan AM, Magnasco L, Viale P, Francisci D, Kofteridis DP, Tiseo G, Giamarellos-Bourboulis EJ, Lagi F, Pinna SM, D'Amico F, La Ferla L, Panagopoulos P, Gattuso G, Sipsas NV, Ruggieri A, Cattaneo A, Corio L, Comandini A, Mascagni P, Bassetti M. Papavramidis T, et al. Among authors: bassetti m. Int J Antimicrob Agents. 2023 Apr;61(4):106746. doi: 10.1016/j.ijantimicag.2023.106746. Epub 2023 Feb 8. Int J Antimicrob Agents. 2023. PMID: 36758778 Free article.
Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study.
Soriano A, Bassetti M, Gogos C, Ferry T, de Pablo R, Ansari W, Kantecki M, Schweikert B, Luna G, Blasi F. Soriano A, et al. Among authors: bassetti m. JAC Antimicrob Resist. 2024 May 27;6(3):dlae078. doi: 10.1093/jacamr/dlae078. eCollection 2024 Jun. JAC Antimicrob Resist. 2024. PMID: 38803385 Free PMC article.
1,008 results